stockrowSTERIS plc
STE Healthcare Medical Devices
STERIS plc’s revenue for fiscal 2026 (year ended March 2026) was $5.9 billion, up 8.73% from fiscal 2025.
- Revenue
- +8.79%
- EPS
- +12.8%
- Free cash flow
- +43.6%
- Total debt
- −0.21%
Quarter to September 2026, against a year earlier
Follow STE
Alert me
STERIS plc 8-K filed Nov 4, 2026
1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
What it says
On November 4, 2026, STERIS and its subsidiaries entered into a $1,600 million revolving credit facility, replacing their existing credit agreement. They also entered into a delayed draw term loan facility of up to $500 million, which is conditional on the acquisition of Xodus Medical, Inc. The revolver matures on November 4, 2031.
-
STERIS, STERIS Corporation, STERIS Limited and STERIS Irish FinCo Unlimited Company are borrowers and guarantors. No borrowings were incurred to refinance and replace the existing agreement. The revolver permits a commitment increase subject to conditions.
The Revolver permits an incremental increase of commitments available thereunder in an amount not to exceed $800 million, subject to certain customary conditions.
-
FinCo is the term loan borrower; STERIS, Corporation and Limited are guarantors. J.P. Morgan SE is administrative agent. The loan matures five years after the acquisition closing date.
The Delayed Draw Term Loan cannot be utilized unless, among other conditions, the acquisition of Xodus Medical, Inc. (the “Xodus Medical Acquisition”) is consummated
-
Quarterly principal payments begin in the second year. The remaining unpaid principal and accrued interest are due at maturity.
No principal payments are due on the Delayed Draw Term Loan in the first year.